Elranatamab monotherapy in the real-word setting in relapsed-refractory multiple myeloma: results of the French compassionate use program on behalf of the IFM
2024

Elranatamab for Relapsed-Refractory Multiple Myeloma

Sample size: 101 publication 10 minutes Evidence: moderate

Author Information

Author(s): Florent Malard, Arthur Bobin, Myriam Labopin, Lionel Karlin, Laurent Frenzel, Murielle Roussel, Marguerite Vignon, Sophie Godet, Thomas Chalopin, Perrine Moyer, Emilie Chalayer, Frederique Orsini Piocelle, Clara Mariette, Carolyne Croizier, Claudine Sohn, Mamoun Dib, Ronan Le Calloch, Nadia Ali-Ammar, Marion Loirat, Omar Benbrahim, Alexandre Payssot, Adrien Trebouet, Aurore Perrot, Xavier Leleu, Mohamad Mohty

Primary Institution: Sorbonne Université, Centre de Recherche Saint-Antoine INSERM UMRs938, Paris, France

Hypothesis

What are the clinical outcomes of elranatamab in a real-world setting for patients with relapsed-refractory multiple myeloma?

Conclusion

Elranatamab shows a 51.5% overall response rate in patients with relapsed-refractory multiple myeloma in a real-world setting.

Supporting Evidence

  • Overall response rate was 51.5% with a complete response or very good partial response rate of 42%.
  • 22% of patients achieved a very good partial response after just one cycle of treatment.
  • At one year, progression-free survival was 34% and overall survival was 42%.
  • Cytokine release syndrome was observed in 45% of patients, but none were severe.

Takeaway

This study looked at how well a new treatment called elranatamab works for people with a tough kind of blood cancer. It found that about half of the patients got better after using it.

Methodology

This was a retrospective analysis of 101 patients who received elranatamab as part of a compassionate use program.

Potential Biases

The study may have selection bias due to the retrospective nature and the specific patient population included.

Limitations

The study included patients who were mostly ineligible for the registration trial, which may affect the generalizability of the results.

Participant Demographics

Median age was 68 years, with 51% male and 49% female participants.

Statistical Information

P-Value

0.0008

Confidence Interval

95% CI: 24.4–43.7 for PFS; 95% CI: 31.7–52.1 for OS

Statistical Significance

p=0.0008

Digital Object Identifier (DOI)

10.1038/s41408-024-01200-w

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication